Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Revance Therapeutics, Inc. (RVNC : NSDQ)
 
 • Company Description   
Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS? peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.

Number of Employees: 495

 
 • Price / Volume Information   
Yesterday's Closing Price: $13.76 Daily Weekly Monthly
20 Day Moving Average: 786,397 shares
Shares Outstanding: 72.77 (millions)
Market Capitalization: $1,001.29 (millions)
Beta: 1.05
52 Week High: $33.83
52 Week Low: $11.65
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -18.53% -8.25%
12 Week 6.42% 16.98%
Year To Date -15.69% 3.32%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1222 DEMONBREUN STREET SUITE 2000
-
NASHVILLE,TN 37203
USA
ph: 615-724-7755
fax: 510-742-3401
jessica.serra@revance.com http://www.revance.com
 
 • General Corporate Information   
Officers
Mark J. Foley - Chief Executive Officer and Director
Angus C. Russell - Chairman and Director
Tobin C. Schilke - Chief Financial Officer
Jill Beraud - Director
Julian S. Gangolli - Director

Peer Information
Revance Therapeutics, Inc. (CORR.)
Revance Therapeutics, Inc. (RSPI)
Revance Therapeutics, Inc. (CGXP)
Revance Therapeutics, Inc. (BGEN)
Revance Therapeutics, Inc. (GTBP)
Revance Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 761330109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 72.77
Most Recent Split Date: (:1)
Beta: 1.05
Market Capitalization: $1,001.29 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.89 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.60 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 39.20
Price/Cash Flow: -
Price / Sales: 11.16
EPS Growth
vs. Year Ago Period: 12.96%
vs. Previous Quarter: -1.08%
Sales Growth
vs. Year Ago Period: 89.95%
vs. Previous Quarter: -2.66%
ROE
03/31/22 - -273.73
12/31/21 - -181.75
09/30/21 - -128.23
ROA
03/31/22 - -45.79
12/31/21 - -46.31
09/30/21 - -45.29
Current Ratio
03/31/22 - 4.01
12/31/21 - 3.66
09/30/21 - 4.46
Quick Ratio
03/31/22 - 3.87
12/31/21 - 3.51
09/30/21 - 4.31
Operating Margin
03/31/22 - -305.27
12/31/21 - -361.59
09/30/21 - -470.81
Net Margin
03/31/22 - -305.27
12/31/21 - -361.59
09/30/21 - -470.81
Pre-Tax Margin
03/31/22 - -305.27
12/31/21 - -361.59
09/30/21 - -475.13
Book Value
03/31/22 - 0.35
12/31/21 - 0.95
09/30/21 - 1.67
Inventory Turnover
03/31/22 - 3.00
12/31/21 - 3.02
09/30/21 - 2.87
Debt-to-Equity
03/31/22 - 14.80
12/31/21 - 4.10
09/30/21 - 2.33
Debt-to-Capital
03/31/22 - 93.67
12/31/21 - 80.39
09/30/21 - 70.00
 

Powered by Zacks Investment Research ©